Lymphomatoid Papulosis Showing ?? T-cell Phenotype

Morimura, Sohshi; Sugaya, Makoto; Tamaki, Zenshiro; Takekoshi, Tomonori; Sato, Shinichi

doi:10.2340/00015555-1145

Cited by 22 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lastly, a 37‐year‐old man diagnosed with γδ phenotype LyP has been reported. The work‐up showed negative results for systemic involvement, and evolved with an indolent clinical behaviour in the 20 months after the initial diagnosis …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

γδ T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T-cell lymphomas

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Type E LyP is an angioinvasive variant with necrosis, haemorrhage, ulceration and CD8 expression . Most recently, a single case report of LyP showing the γδ T‐cell phenotype was published …”

mentioning

confidence: 99%

γδ T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T-cell lymphomas

et al. 2014

View full text Add to dashboard Cite

show abstract

“…29 Subtypes may occur concurrently within the same biopsy or within different specimens taken from the same patient. Other rare pathological variants include γ/δ-type 30 and LyP with 6p25.3 re-arrangement-type 31 . The significance of the γ/δ-variant is unknown.…”

Section: Lymphomatoid Papulosis (Lyp)mentioning

confidence: 99%

CD30 + Lymphoproliferative Disorders of the Skin

Sauder

O’Malley

LeBoeuf

2017

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

SYNOPSIS Primary cutaneous CD30+ lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL) and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of several to hundreds of papulonodules, red or violaceous in color and measuring up to 20mm, usually on the trunk and extremities. Patients with LyP are at increased risk of a secondary malignancy that may be diagnosed before, during or after the diagnosis of LyP and thus should receive ongoing surveillance. pcALCL is characterized by a solitary red to violaceous nodule or tumor greater than 20mm and may occur anywhere on the body. Secondary cutaneous ALCL must be excluded for any patient initially presenting with a cutaneous lesion of ALCL. LyP is benign, limited to the skin and self-resolves with a 5-year survival rate of 100%; pcALCL is usually limited to the skin and responsive to directed therapies, with a 5-year survival of over 95%. Aggressive systemic or multi-agent chemotherapeutic regimens should be avoided.

show abstract

“…The results presented in patients with LyP are not that surprising. In addition to the first case reported by Morimura et al ., Rodríguez‐Pinilla et al . also found a good prognosis in patients with TCRγ + type D LyP.…”

Section: Conflicts Of Interestmentioning

confidence: 72%